In relapsing multiple sclerosis (MS) trials, the key objective centers around diminishing the annualized relapse rate (ARR).
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045
Redefining Relapse in Efficacy Measures for Multiple Sclerosis Treatments: Stephen Krieger, MD; Enrique Alvarez, MD, PhD
Default sub title
minute read
by MedPage Today | March 4, 2024
